title: Should FDG PET/CT be used for the initial staging of breast cancer?
authors.affiliation: Department of Nuclear Medicine, Hôpital Saint-Louis, Assistance publique-Hopitaux de Paris, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France.
authors.forename: David
authors.initials: D
authors.lastname: Groheux
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Marc
authors.initials: M
authors.lastname: Espié
authors.forename: Georges
authors.initials: G
authors.lastname: Baillet
authors.forename: Sylvie
authors.initials: S
authors.lastname: Giacchetti
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Misset
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Moretti
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008197:Lymph Node Excision; D009362:Neoplasm Metastasis / Q000175:diagnosis / Q000000981:diagnostic imaging; D009367:Neoplasm Staging / Q000379:methods; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D021701:Sentinel Lymph Node Biopsy; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18